June 10, 2021: We agree with the FDA’s assessment that the lower burden of disease for COVID-19 in pediatric populations warrants more stringent criteria for safety and efficacy of vaccines than for adults.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Statement of Dr. Diana Zuckerman on FDA’s Approval of Alzheimer’s Drug Aduhelm
June 8, 2021: Dr. Diana Zuckerman, president of NCHR, speaks out against FDA’s approval of the ineffective Alzheimer’s drug aduhelm.
Read More »NCHR’s Statement to FDA Advisory Committee Meeting on Neurological Devices
June 3, 2021: We urge the FDA to regulate the neurological devices in question as Class II, and require the kind of meaningful evidence for new devices that we would want for any device that we use as health professionals, as patients, or as consumers.
Read More »NCHR Comments on USPSTF’s Recommendation Statement Regarding Vitamin Supplementation
June 1, 2021. We support all 3 of USPSTF’s reissued recommendations. However, we urge the USPSTF to also specify the gap in data caused by the lack of information on race in the research.
Read More »NCHR’s Testimony at FDA Advisory Meeting on Teplizumab to Delay Type 1 Diabetes
May 27, 2021. FDA scientists note substantial problems with the study sample. These study shortcomings are even more worrisome since the sample was very small.
Read More »